Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with Type 2 diabetes mellitus

Diabetes Technology and Therapeutics

Volumn 15, Issue 3, 2013, Pages 230-236

  Xie, Lin ^a   Zhou, Steve ^b   Wei, Wenhui ^b   Gill, Jasvinder ^b   Pan, Chunshen ^c   Baser, Onur ^a,d  

^a STATINMED RESEARCH   (United States)

^b SANOFI   (France)

^c ProUnlimited   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE;

ADULT; ARTICLE; DATA BASE; DISPOSABLE EQUIPMENT; ECONOMIC ASPECT; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEMOGLOBIN BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; SYRINGE; TREATMENT DURATION; TREATMENT OUTCOME;

ANXIETY; DIABETES MELLITUS, TYPE 2; DISPOSABLE EQUIPMENT; DRUG DELIVERY SYSTEMS; DRUG DOSAGE CALCULATIONS; EQUIPMENT DESIGN; FEMALE; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN, LONG-ACTING; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PAIN; PATIENT PREFERENCE; PATIENT SATISFACTION; RETROSPECTIVE STUDIES; SYRINGES;

EID: 84875205714     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2012.0253     Document Type: Article

References (27)

1. Brunton S: Initiating insulin therapy in type 2 diabetes: Benefits of insulin analogs and insulin pens. Diabetes Technol Ther 2008;10:247-256
2. DeWitt DE, Hirsch IB: Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 2003;289:2254-2264 (Pubitemid 37430194)
3. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR: Management of hyperglycaemia in type 2 diabetes: A patient- centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55: 1557-1596
4. Korytkowski M, Niskanen L, Asakura T: FlexPen: Addressing issues of confidence and convenience in insulin delivery. Clin Ther 2005;27(Suppl B):S89-S100 (Pubitemid 43866930)
5. Goldstein HH: Pen devices to improve patient adherence with insulin therapy in type 2 diabetes. Postgrad Med 2008;120:172-179
6. Magwire ML: Addressing barriers to insulin therapy: The role of insulin pens. Am J Ther 2011;18:392-402
7. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L; International DAWN Advisory Panel: Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-2679 (Pubitemid 43951158)
8. Korytkowski M, Bell D, Jacobsen C, Suwannasari R: A multicenter, randomized, open-label, comparative, twoperiod crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/ syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25:2836-2848 (Pubitemid 37510593)
9. Carter J, Roberts A: Usability of a pre-filled insulin injection device in a 3-month observational survey of everyday clinical practice in Australia. Curr Med Res Opin 2008;24: 2741-2749
10. Summers KH, Szeinbach SL, Lenox SM: Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther 2004;26:1498-1505 (Pubitemid 39572159)
11. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL: Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third-party managed care claims data. Clin Ther 2006;28:1712-1725 (Pubitemid 44841979)
12. Cobden D, Lee WC, Balu S, Joshi AV, Pashos CL: Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27:948-962 (Pubitemid 46986681)
13. Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R: Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: A retrospective database analysis. Clin Ther 2007;29:1294-1305 (Pubitemid 351172225)
14. Asche CV, Shane-McWhorter L, Raparla S: Health economics and compliance of vials/syringes versus pen devices: A review of the evidence. Diabetes Technol Ther 2010;12(Suppl 1):S-101-S-108
15. Davis SN, Wei W, Garg S: Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract 2011;17:845-852
16. Charlson M, Szatrowski TP, Peterson J, Gold J: Validation of a combined comorbidity index. J Clin Epidemiol 1994;47: 1245-1251 (Pubitemid 24361532)
17. Xie L, Wei W, Pan C, Du J, Baser O: A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens. Adv Ther 2011;28:1000-1011
18. Baser O, Wei W, Baser E, Xie L: Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID. J Med Econ 2011;14:673-680
19. Levin P, Wei W, Wang L, Pan C, Douglas D, Baser O: Combination therapy with insulin glargine and exenatide: Real-world outcomes in patients with type 2 diabetes. Curr Med Res Opin 2012;28:439-446
20. Baser O, Bouchard J, DeLuzio T, Henk H, Aagren M: Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv Ther 2010;27:94-104
21. Zhao Y, Campbell CR, Fonseca V, Shi L: Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care 2012;35:1126-1132
22. Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
23. Hancu N, Czupryniak L, Genestin E, Sourij H: A Pan-European and Canadian prospective survey to evaluate patient satisfaction with the SoloSTAR insulin injection device in type 1 and type 2 diabetes. J Diabetes Sci Technol 2011;5:1224-1234
24. Buysman E, Conner C, Aagren M, Bouchard J, Liu F: Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-nai?ve patients with type 2 diabetes. Curr Med Res Opin 2011;27:1709-1717
25. Clarke A, Dain MP: Dose accuracy of a reusable insulin pen using a cartridge system with an integrated plunger mechanism. Expert Opin Drug Deliv 2006;3:677-683 (Pubitemid 44389028)
26. Marcus A: Diabetes care - insulin delivery in a changing world. Medscape J Med 2008;10:120
27. Shaghouly AA, Shah BR: The prescription of insulin pen devices versus syringes for older people with diabetes. Diabetes Technol Ther 2009;11:439-442